|
| 36263840 | Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia. | Haematologica | 2023 |
| 36108252 | Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia. | J Clin Oncol | 2023 |
| 35482927 | Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. | Blood Adv | 2023 |
| 36263840 | Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia. | Haematologica | 2023 |
| 36380143 | Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy. | Leukemia | 2023 |
| 36725118 | Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials. | Lancet Haematol | 2023 |
| 35482927 | Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. | Blood Adv | 2023 |
| 36725118 | Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials. | Lancet Haematol | 2023 |
| 36108252 | Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia. | J Clin Oncol | 2023 |
| 36380143 | Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy. | Leukemia | 2023 |
| 34192312 | Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium. | Blood | 2022 |
| 35580324 | Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia. | Blood Adv | 2022 |
| 35989458 | Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR). | Pediatr Blood Cancer | 2022 |
| 34192312 | Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium. | Blood | 2022 |
| 34864916 | Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell-like blasts in KMT2A-rearranged leukemia. | Blood | 2022 |
| 34794180 | Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report. | Blood Adv | 2022 |
| 34788386 | Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. | Blood Adv | 2022 |
| 35172563 | Outstanding outcomes in infants with <i>KMT2A</i>-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trial. | Haematologica | 2022 |
| 35180323 | Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. | Am J Hematol | 2022 |
| 34767461 | Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL. | J Clin Oncol | 2022 |
| 35007127 | Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621. | J Clin Oncol | 2022 |
| 34882493 | Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. | J Clin Oncol | 2022 |
| 35121370 | Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma. | Eur J Cancer | 2022 |
| 35580324 | Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia. | Blood Adv | 2022 |
| 35989458 | Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR). | Pediatr Blood Cancer | 2022 |
| 35007127 | Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621. | J Clin Oncol | 2022 |
| 34882493 | Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. | J Clin Oncol | 2022 |
| 35180323 | Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. | Am J Hematol | 2022 |
| 35121370 | Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma. | Eur J Cancer | 2022 |
| 35172563 | Outstanding outcomes in infants with <i>KMT2A</i>-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trial. | Haematologica | 2022 |
| 34864916 | Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell-like blasts in KMT2A-rearranged leukemia. | Blood | 2022 |
| 34788386 | Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. | Blood Adv | 2022 |
| 34794180 | Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report. | Blood Adv | 2022 |
| 34767461 | Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL. | J Clin Oncol | 2022 |
| 32544924 | Intrathecal chemotherapy-associated cerebral vasospasm in children with hematologic malignancies. | Pediatr Res | 2021 |
| 32414848 | Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia. | Haematologica | 2021 |
| 33859388 | Converging genetic and epigenetic drivers of paediatric acute lymphoblastic leukaemia identified by an information-theoretic analysis. | Nat Biomed Eng | 2021 |
| 33694257 | Results of a phase 2, multicenter, single-arm, open-label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia. | Pediatr Blood Cancer | 2021 |
| 33583502 | Neonatal Leukemia. | Clin Perinatol | 2021 |
| 33896328 | Investigational treatment options in phase I and phase II trials for relapsed or refractory acute lymphoblastic leukemia in pediatric patients. | Expert Opin Investig Drugs | 2021 |
| 33846544 | Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631. | Leukemia | 2021 |
| 33623141 | FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631. | Leukemia | 2021 |
| 33601323 | Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE. | Eur J Cancer | 2021 |
| 33651090 | Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. | JAMA | 2021 |
| 33649188 | TCR β chain-directed bispecific antibodies for the treatment of T cell cancers. | Sci Transl Med | 2021 |
| 32544924 | Intrathecal chemotherapy-associated cerebral vasospasm in children with hematologic malignancies. | Pediatr Res | 2021 |
| 34499715 | Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia. | Blood | 2021 |
| 34551384 | Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2021 |
| 33601323 | Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE. | Eur J Cancer | 2021 |
| 33651090 | Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. | JAMA | 2021 |